Klaus Okkenhaug
@klausokken.bsky.social
3.1K followers
460 following
25 posts
Professor of Immunology, Department of Pathology, University of Cambridge.
Research interests: PI3K, immunity, infection, cancer, immunotherapy.
Posts
Media
Videos
Starter Packs
Reposted by Klaus Okkenhaug
Reposted by Klaus Okkenhaug
Klaus Okkenhaug
@klausokken.bsky.social
· Jul 28
De novo-designed pMHC binders facilitate T cell–mediated cytotoxicity toward cancer cells
The recognition of intracellular antigens by CD8+ T cells through T cell receptors (TCRs) is central for adaptive immunity against infections and cancer. However, the identification of TCRs from patie...
www.science.org
Reposted by Klaus Okkenhaug
Reposted by Klaus Okkenhaug
Adrian Liston
@labliston.bsky.social
· Jun 17
Reposted by Klaus Okkenhaug
Reposted by Klaus Okkenhaug
Adrian Liston
@labliston.bsky.social
· Mar 18
Directed disruption of IL2 aggregation and receptor binding sites produces designer biologics with enhanced specificity and improved production capacity
The pleotropic nature of interleukin-2 (IL2) has allowed it to be used as both a pro-inflammatory and anti-inflammatory therapeutic agent, through pro…
www.sciencedirect.com
Reposted by Klaus Okkenhaug
Reposted by Klaus Okkenhaug
Klaus Okkenhaug
@klausokken.bsky.social
· Jan 26
Reposted by Klaus Okkenhaug
Reposted by Klaus Okkenhaug
Klaus Okkenhaug
@klausokken.bsky.social
· Dec 12
Reposted by Klaus Okkenhaug